title: A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin.
abstract: The role of metabolism in daunorubicin (DAUN)- and doxorubicin (DOX)-associated toxicity in cancer patients is dependent on whether the parent drugs or major metabolites, doxorubicinol (DOXol) and daunorubicinol (DAUNol), are the more toxic species. Therefore, we examined whether an association exists between cytotoxicity and the metabolism of these drugs in cell lines from nine different tissues. Cytotoxicity studies using MTT [3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide] cell viability assays revealed that four cell lines [HepG2 (liver), HCT-15 (colon), NCI-H460 (lung), and A-498 (kidney)] were more tolerant to DAUN and DOX than the five remaining cell lines [H9c2 (heart), PC-3 (prostate), OVCAR-4 (ovary), PANC-1 (pancreas), and MCF-7 (breast)], based on significantly higher LC50 values at incubation times of 6, 24, and 48 hours. Each cell line was also assessed for its efficiency at metabolizing DAUN and DOX. The four drug-tolerant cell lines converted DAUN/DOX to DAUNol/DOXol more rapidly than the five drug-sensitive cell lines. We also determined whether exposure to DAUN or DOX induced an increase in metabolic activity among any of these nine different cell types. All nine cell types showed a significant increase in their ability to metabolize DAUN or DOX in response to pre-exposure to the drug. Western blot analyses demonstrated that the increased metabolic activity toward DAUN and DOX correlated with a greater abundance of eight aldo-keto and two carbonyl reductases following exposure to either drug. Overall, our findings indicate an inverse relationship between cytotoxicity and DAUN or DOX metabolism in these nine cell lines.
authors.affiliation: Faculty of Pharmaceutical Sciences (O.S.B., A.S., J.M.L., G.E.C., K.W.R., R.E.R.) and Life Sciences Institute, Department of Zoology, Faculty of Science (T.A.G.), The University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Onkar S
authors.initials: OS
authors.lastname: Bains
authors.forename: András
authors.initials: A
authors.lastname: Szeitz
authors.forename: Joanna M
authors.initials: JM
authors.lastname: Lubieniecka
authors.forename: Gina E
authors.initials: GE
authors.lastname: Cragg
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Grigliatti
authors.forename: K Wayne
authors.initials: KW
authors.lastname: Riggs
authors.forename: Ronald E
authors.initials: RE
authors.lastname: Reid
mesh_terms: D000429:Alcohol Oxidoreductases / Q000378:metabolism*; D000449:Aldehyde Reductase; D000074408:Aldo-Keto Reductases; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000378:metabolism* / Q000633:toxicity*; D018929:Cell Culture Techniques; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000378:metabolism / Q000633:toxicity; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000633:toxicity; D006801:Humans; D007928:Lethal Dose 50; D009928:Organ Specificity; D051381:Rats; D013045:Species Specificity
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; D000429:Alcohol Oxidoreductases; D000074408:Aldo-Keto Reductases; D000449:Aldehyde Reductase; C010013:adriamycinol; C000847:daunorubicinol; D003630:Daunorubicin